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H I G H L I G H T S
• High circulating levels of legumain in patients with stable or acute cardiovascular disease.• High circulating legumain in the acute phase is correlated with improved outcome.• Platelets contain, release and could be sources of circulating legumain.• Extracellular legumain mediates anti-inflammatory responses in primary monocytes.








A B S T R A C T
Background and aims: We have previously found increased levels of the cysteine protease legumain in plasma
and plaques from patients with carotid atherosclerosis. This study further investigated legumain during acute
cardiovascular events.
Methods: Circulating levels of legumain from patients and legumain released from platelets were assessed by
enzyme-linked-immunosorbent assay. Quantitative PCR and immunoblotting were used to study expression,
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while localization was visualized by immunohistochemistry.
Results: In the SUMMIT Malmö cohort (n = 339 with or without type 2 diabetes and/or cardiovascular disease
[CVD], and 64 healthy controls), the levels of circulating legumain were associated with the presence of CVD in
non-diabetics, with no relation to outcome. In symptomatic carotid plaques and in samples from both coronary and
intracerebral thrombi obtained during acute cardiovascular events, legumain was co-localized with macrophages
in the same regions as platelets. In vitro, legumain was shown to be present in and released from platelets upon
activation. In addition, THP-1 macrophages exposed to releasate from activated platelets showed increased le-
gumain expression. Interestingly, primary peripheral blood mononuclear cells stimulated with recombinant le-
gumain promoted anti-inflammatory responses. Finally, in a STEMI population (POSTEMI; n = 272), patients had
significantly higher circulating legumain before and immediately after percutaneous coronary intervention com-
pared with healthy controls (n = 67), and high levels were associated with improved outcome.
Conclusions: Our data demonstrate for the first time that legumain is upregulated during acute cardiovascular
events and is associated with improved outcome.
1. Introduction
Atherosclerosis is the major underlying cause of cardiovascular
disease (CVD), characterized by interaction between accumulated lipids
and inflammation, resulting in persistent low-grade inflammation.
Several immune cells contribute to this non-resolving inflammation
including monocytes/macrophages and T cells. In addition to their role
in thrombus formation, platelets and platelet-mediated inflammation
seem to play a pathogenic role in atherosclerosis, both in the early and
late stage [1].
Proteases secreted by macrophages play important roles in plaque
progression and destabilization by degrading the extracellular matrix
(ECM) in the fibrous cap. Matrix metalloproteases (MMPs) are well
known markers of CVD progression [2]. However, the roles of other
proteases, like members of the cysteine protease family, are less studied.
The cysteine protease legumain (asparaginyl endopeptidase) is thought
to promote ECM degradation by activation of proMMP-2 [3] and pro-
cessing of cathepsins [4] or by direct proteolysis of ECM components like
fibronectin [5,6]. Legumain is present intracellularly in lysosomes, where
it participates in protein degradation, but is also extensively secreted and
found in human serum and plasma [7,8]. Legumain has been shown to be
highly upregulated in unstable carotid plaques and more in unstable than
in stable regions of the same plaque [9,10]. Very recently, high plasma
levels of legumain were measured in patients with complex coronary
lesions [11]. We have recently shown that patients with carotid athero-
sclerosis have increased levels of legumain in plasma and plaques, with
the highest level in patients with symptomatic disease [8]. Within the
atherosclerotic lesion, legumain was co-localized with macrophages, and
in vitro, pro-inflammatory macrophages (M1) secreted legumain espe-
cially after stimulation with cholesterol crystals [8]. To further extend
our findings, we analyzed circulating legumain in two cohorts (SUMMIT
Malmö and POSTEMI), representing patients with stable and acute CVD,
respectively. Furthermore, legumain in thrombus materials and platelets
was investigated, as well as the role of legumain in monocyte-macro-
phage inflammation.
2. Materials and methods
A detailed description of materials and methods are given in the
Supplementary Data.
2.1. Study populations
The cross-sectional SUrrogate markers for Micro- and Macrovascular
hard endpoints for Innovative diabetes Tools (SUMMIT) study was carried
out at four European centers in order to identify vascular changes as-
sociated with clinically manifested CVD in patients with type-2 diabetes
(T2D). The SUMMIT Malmö cohort consisted of 134 subjects with T2D
and CVD, 134 subjects with T2D and no clinical history of CVD, 71 with
CVD but no T2D, and 64 controls without T2D or CVD. The patients
were recruited at Skåne University Hospital, Malmö, Sweden, between
December 2010 and April 2013. The clinical characteristics of the co-
hort are shown in Supplementary Table 1 and have been described
previously [12]. EDTA plasma were sampled and prepared by cen-
trifugation for 10 min at 2000g and samples were stored at −80 °C
until analyzed.
The Post conditioning in ST-Elevation Myocardial Infarction (POSTEMI)
trial was a prospective, randomized, single-center, open-label clinical
trial, investigating the effect of ischemic post-conditioning (IPost) on
infarct size in patients with STEMI treated with primary percutaneous
coronary intervention (PCI) [13] (Supplementary Table 2). The study
design including a detailed cardiac magnetic resonance imaging (CMR)
protocol has previously been reported [14]. Briefly, 272 patients with
first-time STEMI and symptom duration < 6 h were included between
January 2009 and August 2012 at Oslo University Hospital Ullevål,
Norway. Blood sampling was performed before (median 2.8 h after
symptom onset) and immediately after the PCI procedure and further at
day 1 (median 18.3 h after PCI), and at 4 month follow-up. Serum and
plasma was prepared by centrifugation for 10 min at 2000g and samples
were stored at −80 °C until analyzed.
2.2. Ethics
All studies were approved by the local ethical committee and per-
formed in accordance with the principles of the Declaration of Helsinki.
The POSTEMI study which was an intervention trial was also registered
at clinicaltrials.gov (registration number NCT00922675). Written in-
formed consent was obtained from each individual participating in the
studies.
3. Results
3.1. Elevated circulating legumain is associated with the presence of CVD in
non-diabetic patients
In the SUMMIT Malmö cohort, there was a significant correlation
between levels of circulating legumain and CVD (Fig. 1A, left panel),
confirming our previous findings [8]. Higher levels of legumain were
associated with the presence of CVD at baseline in non-diabetics
(n = 135), but not in diabetics (n = 268) (Fig. 1A, right panel). Fur-
thermore, the association between legumain and CVD in non-diabetics
was independent of age, sex and HDL cholesterol (Fig. 1B). At baseline,
levels of circulating legumain were also positively associated with in-
creased right carotid maximal plaque thickness defined as previously
described [12], arterial stiffness (pulse wave velocity) (Fig. 1C), serum
creatinine levels and the width of carotid bulb (sinus) in non-diabetics
(Supplemental Table 3). After 3 years of follow-up, 21 (16%) CV events
(both fatal and non-fatal) were registered in the non-diabetics and 36
(14%) in the diabetics group, but no associations were found between
legumain and CV events at follow-up (Supplemental Table 3).
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3.2. Legumain is co-localized with platelets in carotid plaques and released
upon platelet activation
We have previously shown co-localization of legumain with both pro-
inflammatory M1 and anti-inflammatory M2 macrophages in carotid
plaques [8]. Herein, we confirm the co-localization of legumain with
macrophages (CD68), and also show that legumain is localized in the
same regions as the platelet marker CD41 in symptomatic carotid plaques
(Fig. 2A). By immunoblotting, legumain was actually detected in isolated
platelets, both as the proform (56 kDa) and predominantly as the mature
form (36 kDa) (Fig. 2B). The mature form was shown to be active, by
binding to the legumain-selective activity-based probe (ABP) MP-L01
[15]. Furthermore, when platelet-rich plasma (PRP) was exposed to the
PAR-1 agonist SFLLRN, a rapid and significant release (40% increase
within 10 min) of legumain was induced (Fig. 2C). This legumain release
was inhibited by the PAR-1 antagonist vorapaxar (Fig. 2D).
In an attempt to mimic the inflammatory milieu within athero-
sclerotic lesions, THP-1 monocytes were pre-activated with TNFα be-
fore addition of releasate from thrombin-activated platelets (sPRL) or
unstimulated platelets (uPRL). As shown in Fig. 2E, sPRL significantly
enhanced legumain mRNA expression in TNFα-pre-activated THP-
1 cells compared to uPRL. Activation of TLR4 or TLR2 by LPS or
Pam3Cys, respectively, or IL-1β, all potent inducers of monocyte acti-
vation, did not induce any change in legumain mRNA level.
3.3. Legumain is detected in thrombi materials obtained at the site of
vascular occlusion
Examination of thrombus material removed from the site of the
ruptured plaque showed positive legumain immunostaining, with the
same pattern both in coronary and intracerebral thrombi (Fig. 3A).
Within the thrombi, legumain was co-localized both with monocytes/
macrophages (CD14) and the platelet marker CD41 within the same
region (Fig. 3B). In thrombi analyzed by LC-MS/MS, legumain was also
identified with high confidence (Fig. 3C).
3.4. Legumain promotes development of anti-inflammatory macrophages
We next examined whether recombinant human legumain (100 ng/
mL) affected the mRNA expressions of proto-typical pro-inflammatory
(MCP-1) or anti-inflammatory (IL-10) cytokines, as well as the M2
marker CD163 in primary monocytes from healthy individuals. Whereas
legumain significantly enhanced IL-10 and CD163 mRNA expressions, it
markedly decreased the expression of MCP-1 (Supplemental Fig. S1A). In
the cell supernatant, a similar pattern was seen for MCP-1 and sCD163,
whereas secretion of IL-10 was not modulated by legumain
(Supplemental Fig. S1B). To explore if legumain is involved in macro-
phage polarization, we added recombinant legumain to primary mono-
cytes during differentiation by M-CSF. Legumain significantly reduced
the monocyte activation marker CD14 in both undifferentiating and
differentiating monocytes, and the effect was stable for up to 48 h for the
differentiating cells (Supplemental Fig. S2). Further, legumain reduced
expression of M1 markers in undifferentiating monocytes (CD68, TLR2,
TLR4, iNOS) and in differentiating monocytes (TLR2, TLR4, Fig. 4A); as
well as increased the expression of M2 polarization markers in un-
differentiating monocytes (CD36, CD136) and differentiating monocytes
(MSR-1, CD36, CD136; Fig. 4B). Legumain-stimulation further reduced
the release of pro-inflammatory MPO and MCP-1, without affecting the
release of TNF from the same cells (Fig. 4C). In total, our results suggest a
net anti-inflammatory effect of legumain on primary monocytes.
3.5. Elevated circulating legumain during the acute phase of STEMI
As legumain was found in and released from platelets in vitro and
also co-localized with platelets in thrombi materials, circulating legu-
main was examined in an acute CVD cohort consisting of 272 patients
with STEMI. Patients treated with IPost and conventional PCI had a
similar temporal legumain profile (Supplemental Fig. S3), conse-
quently, the study population was analyzed as a whole. Interestingly,
patients with STEMI had significantly higher serum legumain before
and immediately after PCI (n = 245 and n = 249, respectively) com-
pared with healthy controls (n = 67), followed by a significant decline
Fig. 1. Circulating levels of legumain in diabetics (T2D) and non-diabetics (ND)
with or without CVD.
(A) General linear modelling (two-way ANOVA) was used to calculate sig-
nificant associations between legumain and the main factors, T2D and CVD, and
their interaction. The SUMMIT Malmö cohort consisted of 134 subjects with
T2D and CVD, 134 subjects with T2D and no CVD, 71 with CVD and no T2D.
Estimated marginal means of legumain levels and 95% confidence intervals are
presented (left panel). The percentage of individuals with CVD across tertiles
(T1-T3) of plasma legumain in all individuals, T2D and ND is shown in the right
panel. Chi-square test was used to calculate p values and p values for linear
trends across tertiles. (B) Logistic regression showing association between in-
creasing legumain tertiles (Tertile [T] 1 as reference, T2 red, T3 blue) and CVD
in T2D (top part) and ND (bottom part). M1, univariate; M2 adjusted with age
and sex; M3 adjusted with age, sex and HDL. (C) Right maximal plaque
thickness (Right Bmax, left) and arterial stiffness (pWV, right) according to
tertiles of legumain in T2D and ND. p-values calculated with Kruskal-Wallis
within each group. (For interpretation of the references to colour in this figure
legend, the reader is referred to the Web version of this article.)
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at one day and 4 months after PCI reaching levels comparable to the
healthy controls (Fig. 5A). This pattern was independent of the presence
of diabetes (data not shown). However, although markedly elevated at
baseline, circulating legumain was not associated with infarct size, left
ventricular ejection fraction (LVEF) or myocardial salvage as de-
termined by CMR at 4 months after STEMI. Also, there was a moderate
inverse correlation between legumain measured at admission, before
PCI, and LVEF measured by CMR during the acute phase (Supplemental
Table 5). Heparin was administered to all patients before PCI, and as
heparin has been shown to influence circulating levels of certain cy-
tokines [16], we examined circulating legumain from nine patients with
suspected stable coronary artery disease undergoing elective
angiography. These analyses showed lower legumain levels after he-
parin administration (p = 0.0039) (Fig. 5B), indicating that heparin
treatment might actually underestimate the measured legumain levels.
3.6. Circulating legumain levels are correlated with markers of platelet
activation
Platelet-derived mediators should ideally be measured in platelet-
poor plasma and we therefore measured legumain levels in both plasma
and serum from the same individuals in a sub-group of the STEMI pa-
tients (n = 42) and healthy controls (n = 18). Noteably, legumain
levels were significantly elevated in both plasma and serum in patients
Fig. 2. Legumain is co-localized with platelets in
carotid plaques and released upon platelet activation.
(A) Immunohistochemistry of legumain, CD41 (pla-
telet marker) and CD68 (monocyte/macrophage
marker) in sequential sections of a symptomatic
carotid plaque. The red squares indicate the same
area at 10X and 40X magnification. (B) One re-
presentative immunoblot of legumain (red) without
(left lane) or with (right lane) the legumain-selective
activity-based probe MP-L01 (green) in human pla-
telet lysate (merged; yellow) (n = 3). (C)
Concentration of legumain in platelet-rich plasma
(PRP) after platelet activation using 100 μM SFLLRN
compared to control and measured by ELISA
(n = 4–8). (D) Release of legumain from platelets
preincubated for 90 min with or without 1 μM vor-
apaxar before 10 min stimulation with or without
100 μM SFLLRN (n = 8). Data are presented as
mean ± SEM. *p < 0.05, **p < 0.01, and
***p < 0.001 compared to controls. (E) THP-1
monocytes were pre-activated with 5 ng/mL TNFα
for 96 h prior to culturing for 6 h with platelet re-
leasate from unstimulated (uPRL), or thrombin-acti-
vated (sPRL) platelets. For comparison, TNFα
-treated THP-1 cells were also stimulated with re-
combinant human IL-1β (5 ng/mL), LPS (TLR4 ago-
nist; 5 ng/mL) or P3C (Pam3Cys, TLR2 agonist; 1 μg/
mL). Legumain mRNA expression was measured by
real-time PCR and calculated towards β-actin. Data
are presented as mean ± SEM, n = 3–4. *p < 0.05
vs unstimulated control. (For interpretation of the
references to colour in this figure legend, the reader
is referred to the Web version of this article.)
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compared to controls (Fig. 5C). As expected, legumain levels as well as
levels of P-selectin and platelet factor 4 (PF4), two established platelet-
derived markers, were higher in serum compared to plasma, in both
patients and controls (Fig. 5D). In addition, plasma levels of these three
platelet-derived molecules were significantly correlated in the STEMI
patients, but not in healthy controls (Fig. 5E).
Fig. 3. Legumain is present cerebrovascular and coronary thrombus material.
(A) Immunostaining of legumain in thrombus material from one representative patient (n = 5) with acute ischemic stroke (left) removed from the site of plaque
rupture; and from one representative patient (n = 5) with STEMI undergoing PCI (right). The red squares indicate the same area at 10X and 40X magnification. (B)
Fluorescent double-staining of legumain (green) and CD41 (platelet marker; red, left), and CD14 (macrophage marker; red, right). Nuclei are stained blue by DAPI.
Merge of the individual stainings. One representative staining of n = 4. (C) Protein identification by LC-MS/MS from intracranial thrombus material identified two
unique peptides for legumain (upper panels show the annotated MS/MS spectra for the identified peptides and lower panel shows the identified peptides highlighted
from the full protein sequences). The overall sequence coverage for legumain was 7.1% and Mascot identification score was 120. (For interpretation of the references
to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Primary monocytes (medium) and differentiating primary monocytes (M-CSF, 20 ng/mL; R&D) were stimulated with 100 ng/mL recombinant human
prolegumain (black bars) or PBS (control, red and blue bars) and evaluated for gene expression of M1 (CD68, TLR2, TLR4, iNOS) and M2 (Arg1, MSR1, CD36, CD163)
macrophage markers after 6 h (A and B, respectively) and release of inflammatory mediators after 72 h (C). ***p < 0.001, **p < 0.01 and *p < 0.05 versus control
(red or blue bars). US, unstimulated. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 5. Circulating legumain during STEMI in the POSTEMI cohort.
(A) Legumain was measured in serum from patients with STEMI collected before (pre; n = 245) and immediately after (post; n = 249) the PCI procedure, at day 1
(median 18.3 h after PCI, n = 243), and 4 (n = 249) and 12 months (n = 241) follow-up and in 67 controls (CTR). Data are presented as geometric means with 95%
CI. *p < 0.001 vs controls, obtained by Kruskal-Wallis test, #p < 0.001 vs day 1, 4 and 12 months, respectively, obtained by Wilcoxon signed rank test. (B)
Legumain serum levels in patients with stable coronary artery disease (n = 9) referred to elective coronary angiography before and after heparin administration. The
first sample was drawn before the coronary angiography procedure and administration of unfractionated heparin and the second sample was drawn after admin-
istration of heparin at the end of the procedure. Data are presented for each subject. The p-value is obtained by Wilcoxon matched-pairs signed rank test. (C)
Legumain, (D) P-selectin (PSEL) and platelet factor 4 (PF4) in plasma (P) and serum (S) from STEMI patients (red; n = 42) and healthy controls (blue; n = 18)
measured by ELISA. (E) Correlation between plasma legumain and P-selectin and platelet factor 4. (F) Legumain levels in survivors (alive) and non-survivors (dead)
measured pre- and post-PCI, at 1 day and after 4 months, and compared by the Mann Whitney U test. *p < 0.05. (G) Cox regression analyses of legumain (log
transformed expressed per SD) levels pre- and post-PCI and all-cause mortality. Hazard ratio (HR) and 95% CI are shown for univariate and multi-variate (adjusted
for age and troponin T (TnT)) analyses. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
N.N. Lunde, et al. Atherosclerosis 296 (2020) 74–82
80
3.7. Low circulating legumain levels are associated with increased mortality
in the STEMI population
A total of 26 deaths (10% of the total cohort) were registered after a
median of 70 months of follow-up after STEMI. Interestingly, legumain
levels in blood samples drawn before and after PCI were lower in patients
who died during follow-up (Fig. 5F). Furthermore, evaluated as a con-
tinuous variable, legumain levels both before and after PCI were asso-
ciated with a reduced hazard ratio of all-cause mortality that was more or
less unmodified when adjusting for age and TnT release (Fig. 5G).
4. Discussion
We have previously shown enhanced expression of legumain within
symptomatic carotid plaques [8], and in the current study we present
novel data on legumain regulation during acute cardiovascular events
and the presence of active legumain in platelets. We found that circu-
lating legumain levels were upregulated in the stable and particular in
the acute phase of CVD (STEMI). In the latter population, high legumain
levels were associated with improved outcome at follow-up. Moreover,
legumain was co-localized with macrophages and platelets in sympto-
matic carotid plaques, as well as in both coronary and intracerebral
thrombi obtained during acute cardiovascular events. Furthermore, le-
gumain was released from platelets upon PAR-1 activation, and was
upregulated in THP-1 monocytes when exposed to releasate from acti-
vated platelets. Interestingly, legumain reduced the monocyte activation
marker CD14 in primary monocytes, and reduced the release of proin-
flammatory cytokines from both undifferentiated primary monocytes,
and from monocytes undergoing macrophage differentiation. Legumain
further downregulated M1 markers and upregulated M2 markers in both
undifferentiated monocytes and differentiating monocytes, stimulating
the development of an anti-inflammatory macrophage phenotype. This
suggest that legumain could mediate platelet-monocyte interactions that
could involve anti-inflammatory responses. Our findings of strong legu-
main immunostaining at the site of thrombus formation in STEMI pa-
tients and in patients with acute ischemic stroke further support a role for
legumain in modulation of plaque stability.
A major finding in the present study was the observation of platelets
as a source of legumain. Legumain is expressed in a wide range of cell
types including various immune, stromal and tumor cells. We have re-
cently reported increased secretion of legumain from M1 macrophages
[8], indicating multiple sources of legumain. One study using a pro-
teomic approach has previously reported legumain as one of approxi-
mately 4500 proteins stored in human platelets [17]. Our study is, to the
best of our knowledge, the first report showing that platelets not only
contain legumain, but also release this cysteine protease upon activation.
In platelets, both the pro- and mature form were detected by im-
munoblotting, with highest level of the mature form. Notably, the mature
form is active as it binds the legumain-selective ABP MP-L01 [15]. Active
legumain in platelets might indicate lysosomal storage, as legumain is a
lysosomal protease and low pH is required for activation and proteolytic
activity of legumain and other proteases, and shown for cathepsin D in
platelets [18]. However, after secretion, prolegumain can be activated in
less acidic environments when stabilized by the cell surface αvβ3 in-
tegrin, glycosaminoglycans or cystatins present extracellularly [15,19].
Also, the inflamed arterial wall in atherosclerosis creates a local acidic
milieu that could activate prolegumain extracellularly. In carotid pla-
ques, we have previously shown high expression of mature legumain [8].
However, legumain could also be stored in α-granules since these ve-
sicles are fully released within a few minutes [20], which fits with the
release pattern of legumain from platelets. The ability of the selective
PAR-1 antagonist vorapaxar to block release of legumain, suggests a
direct involvement of PAR-1 in legumain secretion from platelets.
The platelet releasate comprises a multitude of inflammatory and
vasoactive substances which can modulate endothelial cells and
monocytes/macrophages within the atherosclerotic lesion [21]. We
show that the releasate from activated platelets significantly enhances
legumain mRNA expression in TNFα-pre-activated THP-1 monocytes, in
a setting mimicking the in vivo situation within an inflammatory
atherosclerotic lesion. Notably, well-known activators of monocyte/
macrophage (i.e. TLR2/4 agonists and IL-1β) had no effects on legu-
main expression in these cells. Our findings suggest that legumain could
be operating in the interaction between monocytes/macrophages and
platelets to modulate plaque stability. Indeed, we found co-localization
of legumain with both monocytes/macrophages and platelets within
symptomatic carotid plaques and in thrombus material obtained at the
site of thrombus formation in STEMI patients and in patients with is-
chemic stroke. This observation suggests that legumain, as a novel
player in platelet-monocyte interactions, also operate in vivo during
acute cardiovascular events.
The association between diabetes and cardiovascular disease is well
documented and type 2 diabetes doubles the risk of developing cor-
onary artery disease. As far as we know, this is the first study in-
vestigating legumain in a diabetic population. In patients with stable
CVD, an association between high circulating legumain and cardio-
vascular events was only seen in the non-diabetic patients. Plasma le-
vels of other proteases, like MMP-7 and -12, have been shown to be
elevated in type-2 diabetes and to be associated with more severe
atherosclerosis and increased incidence of coronary events [22]. The
origin of circulating legumain in diabetics compared to non-diabetics is
of interest. Circulating legumain in diabetics could originate from other
tissues than atherosclerotic lesions, as suggested for the mentioned
MMPs. As observed for legumain, the association between MMP-12 and
pulse wave velocity was stronger in non-diabetics than in diabetics,
although diabetics had higher plasma levels of MMP-12 than the non-
diabetics. The different observations of legumain in non-diabetic and
diabetic subjects need further investigations. However, these associa-
tions with outcome were not found in the STEMI study and our data
should be interpreted with caution and need to be confirmed in larger
study populations. Interestingly, during acute CVD (STEMI population),
low circulating legumain levels during the acute phase were associated
with increased mortality during follow-up. The reasons for these ap-
parent discrepancies are at present not clear, but could reflect that le-
gumain is differently regulated during stable compared to acute car-
diovascular events. In fact, the rapid increase of circulating legumain
during STEMI, with normalization within 24 h could suggest that le-
gumain is rapidly cleared from the circulation, and that legumain is not
an optimal biomarker in patients with stable disease. During an acute
cardiovascular event, however, measurement of circulating legumain
could potentially give additional prognostic information. Higher levels
of legumain in serum compared to plasma further suggest that legumain
is secreted upon platelet activation. Thus, measurements of platelet-
derived markers in serum samples may in some degree also reflect the
release of these molecules during coagulation ex vivo, which will not be
an issue when using platelet-poor plasma. In a subset of STEMI patients,
we did however see increased levels of legumain also in plasma sam-
ples, and plasma legumain significantly correlated with P-selectin and
PF4, two soluble markers of platelet activation. Taken together, these
analyses suggest that the raised levels of legumain in STEMI patients are
not merely an ex vivo phenomenon, but reflect enhanced in vivo release
of this molecule from platelets in the circulation of STEMI patients.
A potential role of legumain during modulation of plaque stability is
at present not clear. Legumain has been shown to activate innate im-
munity, promote apoptosis, disturb immune tolerance and modulate
ECM degradation and is also involved in disorders like Alzheimer's
disease and cancer [19]. In STEMI, however, we found that high cir-
culating legumain levels were associated with improved outcome. This
may be contradictory to the suggested detrimental role in inflammation
and ECM remodeling, but there are also data suggesting a role for le-
gumain in tissue repair [23]. Moreover, in an experimental mouse
model legumain was shown to mediate anti-inflammatory and pro-re-
solving effects of M2 macrophages by attenuating renal interstitial
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fibrosis in obstructive nephropathy [24]. Indeed, the present study in-
dicates that legumain induces polarization of anti-inflammatory mac-
rophages, shown by an upregulation of several genes such as CD163,
which could potentially reflect polarization of monocytes towards the
M2 phenotype, while downregulating a M1 phenotype. Also, legumain
may contribute to reduce inflammation by dampning monocyte acti-
vation through downregulation of the activation marker CD14, which
was found to be downregulated up to 48 h after legumain stimulation.
Thus, although some data may suggest that legumain could contribute
to plaque destabilization, forthcoming studies should more thoroughly
examine the consequences of enhanced legumain levels during STEMI
and other acute cardiovascular events. The present study has some
limitations such as lack of functional legumain data and the fact that
size of both study populations yields relatively low numbers of events
during follow-up.
Nonetheless, our data demonstrate for the first time that legumain is
markedly upregulated during acute cardiovascular events. Also, the
presence of legumain in acute thrombus material suggests that legu-
main could be a novel player in modulation of plaque stability, oper-
ating in the interaction between platelets and monocytes/macrophages,
potentially mediating anti-inflammatory effects.
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